Histopathological and electrophysiological indices of rotenone-evoked dopaminergic toxicity: Neuroprotective effects of acetyl-L-carnitine

Neuroscience Letters

Volumn 606, Issue , 2015, Pages 53-59

  Sarkar, S ^a   Gough, B ^a   Raymick, J ^a   Beaudoin, M A ^a   Ali, S F ^a   Virmani, A ^b   Binienda, Z K ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b Research   (Netherlands)

Author keywords

Dopamine transporter (DAT); Midbrain; Peripheral nerves; Rotenone; Tyrosine hydroxylase

Indexed keywords

CD11B ANTIGEN; DOPAMINE TRANSPORTER; GLIAL FIBRILLARY ACIDIC PROTEIN; LEVACECARNINE; PARAFORMALDEHYDE; ROTENONE; TYROSINE 3 MONOOXYGENASE; ACETYLCARNITINE; DOPAMINE; NEUROPROTECTIVE AGENT; PESTICIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; ELECTROPHYSIOLOGY; HISTOPATHOLOGY; MALE; MOTOR NERVE CONDUCTION; MUSCLE ACTION POTENTIAL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; RAT; SUBSTANTIA NIGRA PARS COMPACTA; ACTION POTENTIAL; ANIMAL; CAUDATE NUCLEUS; DRUG EFFECTS; INNERVATION; METABOLISM; MICROGLIA; NERVE CONDUCTION; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA; TAIL;

ACETYLCARNITINE; ACTION POTENTIALS; ANIMALS; CAUDATE NUCLEUS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MICROGLIA; MUSCLE, SKELETAL; NEURAL CONDUCTION; NEUROPROTECTIVE AGENTS; PESTICIDES; PUTAMEN; RATS, SPRAGUE-DAWLEY; ROTENONE; SUBSTANTIA NIGRA; TAIL; TYROSINE 3-MONOOXYGENASE;

EID: 84940738985     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.08.044     Document Type: Article

References (22)

1. Ferrante R.J., Schulz J.B., Kowall N.W., Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res. 1997, 753:157-162.
2. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 2003, 23:10756-10764.
3. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
4. Cannon J.R., Geghman K.D., Tapias V., Sew T., Dail M.K., Li C., Greenamyre J.T. Expression of human E46K-mutated alpha-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Exp. Neurol. 2013, 240:44-56.
5. Lin T.K., Cheng C.H., Chen S.D., Liou C.W., Huang C.R., Chuang Y.C. Mitochondrial dysfunction and oxidative stress promote apoptotic cell death in the striatum via cytochrome c/caspase-3 signaling cascade following chronic rotenone intoxication in rats. Int. J. Mol. Sci. 2012, 13:8722-8739.
6. Samantaray S., Ray S.K., Banik N.L. Calpain as a potential therapeutic target in Parkinson's disease. CNS Neurol. Disord. Drug Targets 2008, 7:305-312.
7. Binienda Z.K., Beaudoin M.A., Gough B., Ali S.F., Virmani A. Assessment of 3-nitropropionic acid-evoked peripheral neuropathy in rats: neuroprotective effects of acetyl-L-carnitine and resveratrol. Neurosci. Lett. 2010, 480:117-121.
8. Gagnaire F., Marignac B., de Ceaurriz J. Diethylbenzene-induced sensorimotor neuropathy in rats. J. Appl. Toxicol. 1990, 10:105-112.
9. Desi L., Nagymajtenyi, Papp A., Schulz H. Experimental model studies of pesticide exposure. Neurotoxicology 1998, 19:611-616.
10. Fricker B., Muller A., Rene F. Evaluation tools and animal models of peripheral neuropathies. Neurodegener. Dis. 2008, 5:72-108.
11. Virmani A., Binienda Z. Role of carnitine esters in brain neuropathology. Mol. Aspects Med. 2004, 25:533-549.
12. Hauser D.N., Hastings T.G. Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol. Dis. 2013, 51:35-42.
13. Solutol® HS 15 polyethyleneglycol 660 hydroxystearate as nonionic solubilizer for injection solutions. BASF Tech. Leafl. MEF 1986, 151e.
14. Binienda Z.K., Sarkar S., Mohammed-Saeed L., Gough B., Beaudoin M.A., Ali S.F., Paule M.G., Imam S.Z. Chronic exposure to rotenone, a dopaminergic toxin, results in peripheral neuropathy associated with dopaminergic damage. Neurosci. Lett. 2013, 541:233-237.
15. Höglinger G.U., Féger J., Prigent A.P., Michel P.P., Parain K., Champy P., Ruberg M., Oertel W.H., Hirsch E.C. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 2003, 84:491-502.
16. Dunnett S.B., Björklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 1999, 399(Suppl):A32-A39.
17. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2001, 2:325-332.
18. Ren Y., Liu W., Jiang H., Jiang Q., Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 2005, 280:34105-34112.
19. Ferris C.F., Marella M., Smerkers B., Barchet T.M., Gershman B., Matsuno-Yagi A., Yagi T. A phenotypic model recapitulating the neuropathology of Parkinson's disease. Brain Behav. 2013, 3:351-366.
20. Bieber L.L. Carnitine. Ann. Rev. Biochem. 1988, 57:261-283.
21. Beal M.F. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J. Bioenerg. Biomembr. 2004, 36:381-386.
22. Virmani A., Gaetani F.A., Binienda Z.K., Xu A.B., Duhart H.B., Ali S.F. Role of mitochondrial dysfunction in neurotoxicity of MPP+: partial protection of PC12 cells by acetyl-l-carnitine. Ann. N. Y. Acad. Sci. 2006, 1025:267-273.